Suchergebnisse - "Richardson, Paul G"

PubPharm (767)

41

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001) : a multicentre, multicohort, open-label, phase 1/2 trial

enthalten in: The Lancet. Haematology | 2022

von Lonial, S. | Popat, R. | Hulin, C. | +18

CommentIn: Lancet Haematol. 2022 Nov;9(11):e799-e801. - PMID 36209763

42

Evaluation of isatuximab in patients with soft-tissue plasmacytomas : An analysis from ICARIA-MM and IKEMA

enthalten in: Leukemia research | 2022

von Beksac, M. | Spicka, I. | Hajek, R. | +9

43

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma : Analysis of vascular thrombotic events in the GRIFFIN study

enthalten in: British journal of haematology | 2022

von Sborov, D. | Baljevic, M. | Reeves, B. | +18

44

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma : differential mechanisms of action and recent clinical trial outcomes

enthalten in: Annals of hematology | 2022

von Leleu, X. | Martin, T. | Weisel, K. | +13

45

Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma

enthalten in: Leukemia & lymphoma | 2022

von Ho, M. | Moscvin, M. | Low, S. | +8

46

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma : a practical review

enthalten in: British journal of haematology | 2022

von McCaughan, G. | Gandolfi, S. | Moore, J. | +1

47

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma : subgroup analyses from ICARIA-MM and IKEMA

enthalten in: Haematologica | 2022

von Martin, T. | Richardson, P. | Facon, T. | +9

48

Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma

enthalten in: Blood advances | 2022

von O'Donnell, E. | Shapiro, Y. | Yee, A. | +15

49

Melphalan flufenamide for relapsed/refractory multiple myeloma

enthalten in: Drugs of today (Barcelona, Spain : 1998) | 2022

von Nadeem, O. | Mateos, M. | Efebera, Y. | +5

50

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

enthalten in: Annals of hematology | 2022

von Leleu, X. | Martin, T. | Weisel, K. | +12